An article on the Strauss Group website describes probiotic yogurts developed to help regulate digestion and improve symptoms of IBS. The yogurts contain Bifidus Actiregularis bacteria and bio-bacteria. Studies focused on the survival of the bacterium in the gastrointestinal tract and its functionality cover “digestive comfort” a term used to define a well-functioning digestive system without gas, bloating, constipation, etc. The studies specifically relate to the elderly and to women. Probiotics have been shown to help improve brain activity and may be helpful for the nervous system and PD patients. Studies suggest that probiotics may help PD patients by decreasing pro-inflammatory cytokines, oxidative stress, and potentially pathogenic bacterial overgrowth.
yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019
The product containing yogurt with polydextrose, B. lactis HN019 and L. acidophilus NCFM® significantly shortened colonic transit time after two weeks
Many bacteria, such as Escherichia coli found in the large intestine, can synthesize vitamin K2 (menaquinone-7 or MK-7, up to MK-11), but not vitamin K1 (phylloquinone).
Vitamin K – Wikipedia
en.m.wikipedia.org › wiki › Vitamin_K
Gut bacteria that produce k2:
k2 lower INR:
Fish Oil 3gr per day
Zinc carnosine 2X75 mg /day
use coconut oil – oil pulling , for mouth higene, especially against gingivalis
see also postt on colostrun, here
in normal physiology, glutamine plays a key role in signalling in enterocytes that are part of the intestinal barrier, but it is not clear if supplementing the diet with glutamine is helpful in conditions where there is increased intestinal permeability.
Prebiotics and certain probiotics such as Escherichia coli Nissle 1917 have been found to reduce increased intestinal permeability. Lactobacillus rhamnosus, Lactobacillus reuteri, and Faecalibacterium prausnitzii have also been shown to significantly reduce increased intestinal permeability.
Larazotide acetate (previously known as AT-1001) is a zonulin receptor antagonist that has been probed in clinical trials. It seems to be a drug candidate for use in conjunction with a gluten-free diet in people with celiac disease, with the aim to reduce the intestinal permeability caused by gluten and its passage through the epithelium, and therefore mitigating the resulting cascade of immune reactions. read more>>